WO2010018067A1 - Verfahren zur herstellung von piperazindion-derivaten - Google Patents
Verfahren zur herstellung von piperazindion-derivaten Download PDFInfo
- Publication number
- WO2010018067A1 WO2010018067A1 PCT/EP2009/059859 EP2009059859W WO2010018067A1 WO 2010018067 A1 WO2010018067 A1 WO 2010018067A1 EP 2009059859 W EP2009059859 W EP 2009059859W WO 2010018067 A1 WO2010018067 A1 WO 2010018067A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- halogen
- formula
- methyl
- alkoxy
- Prior art date
Links
- 0 *C(*)(C(NC1)=O)NC1=O Chemical compound *C(*)(C(NC1)=O)NC1=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Definitions
- the present invention relates to a process for the preparation of piperazinedione derivatives of the formula I,
- R 1 hydrogen, C 1 -C 8 -alkyl, C 3 -C 4 -alkenyl, C 3 -C 4 -alkynyl and C 1 -C 8 -alkylcarbonyl
- R 11 is hydrogen, Ci-C4 -alkyl, Ci-C 4 haloalkyl, Ci-C4-alkoxy and CrC 4 -HaIo- alkoxy;
- R 3, R 4 are independently hydrogen, Ci-C 8 alkyl and Ci-C8-haloalkyl, where the groups by halogen, OH, CN, NO2, Ci-C 8 -alkyl, C 2 -C 8 - alkenyl, C 2 -C 8 - alkynyl, C 3 -C 8 cycloalkyl, Ci-C8-haloalkyl, Ci-C8-alkoxy, Ci-C8-halo-alkoxy, 0-C (O) R 12, Phenyl, phenoxy and benzyloxy, which cyclic groups may be unsubstituted or substituted by 1 to 5 groups R a ,
- R a is halogen, CN, NO2, Ci-C 8 -alkyl, C 8 haloalkyl, C 2 -C 4 alkenyl, C 8 -
- R 12 is d-C ⁇ -alkyl, C 3 -C 8 -alkenyl, C 3 -C 8 -alkynyl and C 3 -C 8 -cycloalkyl; mean,
- H 2 NR 1 M in the R 1 is hydrogen and Ci-C 8 alkyl, which may be optionally substituted, means
- Y is halogen, C 1 -C 6 -alkoxy or phenyloxy, which may be unsubstituted or partially or completely substituted by groups R a and R 2 , R 3 and R 4 have the meaning given initially, are reacted under basic conditions in an aqueous solvent.
- Piperazinedione derivatives of the formula I are valuable intermediates, for example for the preparation of pharmaceutical and herbicidal active compounds of the formula IV.
- A is an optionally substituted.
- mono- or bicyclic carbo- or heteroaromatic ring, RJ-R 3 , are as defined above and R 5 has one of the meanings given for R 1 -R 3 ,
- R 41, R 42 is hydrogen, Ci-C 8 alkyl and Ci-C 8 alkoxy, where the groups by halogen, OH, CN, d-Cs-alkyl, Ci-C 8 haloalkyl, C 3 -C 8 - Cycloalkyl, C 1 -C 8 -alkoxy,
- R a is halogen, CN, NO 2, C -C alkyl 4 -alkyl, C 2 -C 4 alkenyl, C 2 -C kinyl 4 -alkyl, Ci-C 4 alkoxy, 0-C (O) R 12, Phenoxy and benzyloxy, which are cyclic groups by 1 to 5
- R a groups such as halogen, CN, NO2, Ci-C 4 -alkyl, C 8 haloalkoxy, C 8 - haloalkyl groups;
- R 12 is C 1 -C 8 -alkyl, C 3 -C 8 -alkenyl, C 3 -C 8 -alkynyl and C 3 -C 8 -cycloalkyl;
- n is O, 1, 2, 3, 4 or 5.
- Cyclizations of amino acid derivatives with ammonia, or amines to Piperazindi- onen are, for example, in Tetrahedron Lett. 1971, p.2499; J. Bull. Chem. Soc. Jpn. 1975, Vol. 48, p.2584; Int. J. Prept. Prot. Res. 28 (6), p.579-585 (1986); Heterocycles 2000, Vol. 52 (3), p.1231-1239; Tetrahedron Vol. 58 (6), pp. 1173-1183 (2002); Synth. Commun. 2004, Vol. 34 (22), p. 41 11 -18; Arch. Pharm. 2005, Vol. 338 (5), pages 281-90.
- the object of the invention was to provide a process for preparing the piperazinedione derivatives of the formula I, which is suitable for industrial use and proceeds from commercially readily available starting materials.
- This reaction is usually carried out at temperatures of 2O 0 C to 14O 0 C, preferably 4O 0 C to 12O 0 C, in an inert organic solvent in the presence of a base and optionally a catalyst [see. Arch. Pharm. 2005, Vol. 338 (5), pp. 281-90].
- Suitable solvents are water, aliphatic hydrocarbons such as pentane, hexane, cyclohexane and petroleum ether, aromatic hydrocarbons such as toluene, o-, m- and p-xylene, ethylbenzene, mesitylene, halogenated hydrocarbons such as methylene chloride, chloroform and chlorobenzene, dichlorobenzene, benzotrifluoride, Ether like
- a phase transfer catalyst can be used for the cyclization.
- the reaction of volatile amines e.g. Ammonia, especially aqueous ammonia
- the reaction can be carried out in a closed apparatus.
- an aqueous amine solution the addition of a solvent can be dispensed with.
- the cyclization with aqueous ammonia may be carried out under pressure without organic solvent in the presence of a phase transfer catalyst.
- the cyclization with aqueous ammonia may be conducted under pressure without organic solvent in the absence of a phase transfer catalyst.
- Bases used are generally the amines II used, and inorganic compounds such as alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide, alkali metal and alkaline earth metal oxides such as lithium oxide, sodium oxide, calcium oxide and magnesium oxide, alkali metal and alkaline earth metal carbonates such as lithium carbonate, Potassium carbonate and calcium carbonate, as well as alkali metal bicarbonates, such as sodium bicarbonate, alkylmagnesium halides, such as methylmagnesium chloride, and also suitable organic bases, for example tertiary amines such as trimethylamine, triethylamine, tri-butylamine, di-isopropylethylamine and N-methylpiperidine, pyridine, substituted pyridines such as collidine, lutidine and 4-dimethylaminopyridine and bicyclic amines. Particularly preferred are amines of the formula II, alkali metal
- the bases are generally used in catalytic amounts, but they can also be used equimolar, in excess or optionally as solvent.
- phase transfer catalysts are used. They are known to the person skilled in the art [cf. WO 2006/11 1583]. Tetraalkyl- or tetraarylammonium and phosphonium halides, tetrakis (dialkyl or diarylamino) phosphonium halides and alkylguanidinium halide derivatives are usually suitable.
- the starting materials are generally reacted with one another in equimolar amounts. It may be advantageous for the yield to use II in an excess based on III.
- the compounds of the formula II used are C 1 -C 4 -alkylamines.
- the compounds of the formula III are obtainable, for example, from the reaction of ⁇ -amino acid derivatives of the formula III.1 with ⁇ -haloacetic acid derivatives of the formula III.2, in which the variables X are halogen, preferably chlorine, Y is halogen or C 1 -C 4 -alkoxy C 1 -C 4 -alkoxy, such as methoxy or ethoxy, in particular ethoxy, and Y 'is halogen or C 1 -C 4 -alkoxy, preferably halogen, in particular chlorine.
- X are halogen, preferably chlorine
- Y is halogen or C 1 -C 4 -alkoxy C 1 -C 4 -alkoxy, such as methoxy or ethoxy, in particular ethoxy
- This reaction is usually carried out at temperatures from -1O 0 C to 40 0 C, preferably O 0 C to 2O 0 C, in an inert organic solvent in the presence of a base [see. J. Org. Chem. 2004, 69 (5); 1542-47].
- Suitable solvents are water, aliphatic hydrocarbons such as pentane, hexane, cyclohexane and petroleum ether, aromatic hydrocarbons such as toluene, o-, m- and p-xylene, ethylbenzene, mesitylene, halogenated hydrocarbons such as methylene chloride, chloroform and chlorobenzene, dichlorobenzene, benzotrifluoride, ethers such as diethyl ethers, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, dioxane, anisole and THF, nitriles such as acetonitrile and propionitrile, ketones such as acetone, methyl ethyl ketone, diethyl ketone and tert-butyl methyl ketone, and DMSO, sulfolane, DMF, DMA, N
- Suitable bases are generally inorganic compounds such as alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide, alkali metal and alkaline earth metal oxides such as lithium oxide, sodium oxide, calzium oxide and magnesium oxide, alkali metal and alkaline earth metal carbonates such as lithium carbonate, potassium carbonate and calcium carbonate and Alkali metal hydrogencarbonates such as sodium bicarbonate, also organic bases, for example tertiary amines such as trimethylamine, triethylamine, tributylamine, di-isopropylethylamine and N-methylpiperidine, pyridine, substituted pyridines such as collidine, lutidine and 4-dimethylaminopyridine and bicyclic amines into consideration. Particularly preferred are alkali metal and alkaline earth metal hydroxides such as NaOH, KOH and Ca (OH) 2 .
- the bases are generally used in catalytic amounts, they are preferably used equimolar, in excess or optionally as a solvent.
- phase transfer catalysts are used. They are known to the skilled person. Usually, those mentioned in WO 2006/11 1583 come into question. For practical reasons, tetraalkyl or tetraarylammonium and phosphonium halides, tetrakis (dialkyl or diarylamino) phosphonium halides and alkylguanidinium halide derivatives are preferred.
- the starting materials are generally reacted with one another in equimolar amounts. It may be advantageous for the yield to use III.2 in an excess relative to III.1.
- the preparation of the compounds of the formula I takes place in a one-pot process from the compounds III.1, which are first aeylated with compounds III.2 and the resulting compounds III are reacted without isolation with the amine II.
- protecting group SG acetophenone, benzaldehyde, benzophenone and pivalyl aldehyde, especially benzaldehyde, are preferred as protecting group SG and Y is preferably alkoxy.
- the protective group is split off and
- III.3a (or III.3a ") with III.4 is usually carried out at temperatures of from -1 O 0 C to 4O 0 C, preferably 0 ° C to 2O 0 C in an inert organic solvent in the presence of a Base [see Synth.Commun., 2005, 35 (8), 1 129-34].
- Suitable solvents are water, aliphatic hydrocarbons such as pentane, hexane, cyclohexane and petroleum ether, aromatic hydrocarbons such as toluene, o-, m- and p-xylene, ethylbenzene, mesitylene, halogenated hydrocarbons such as methylene chloride, chloroform and chlorobenzene, dichlorobenzene, benzotrifluoride, ethers such as Diethyl ether, diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, dioxane, anisole and THF, nitriles such as acetonitrile and propionitrile, ketones such as acetone, methyl ethyl ketone, diethyl ketone and tert-butyl methyl ketone, alcohols such as methanol, ethanol, n-propanol, is
- Bases generally include inorganic compounds such as alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide, alkali metal and alkaline earth metal oxides such as lithium oxide, sodium oxide, calcite oxide and magnesium oxide, alkali metal and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride, Alkali metal amides such as lithium amide, sodium amide and potassium amide, alkali metal and alkaline earth metal carbonates such as lithium carbonate, potassium carbonate and calcium carbonate, and alkali metal hydrogencarbonates such as sodium hydrogencarbonate, organometallic compounds, in particular alkali metal alkyls such as methyllithium, butyl lithium and phenyl lithium, alkyl magnesium halides such as methyl magnesium chloride and alkali metal and alkaline earth metal alkoxides such as sodium methoxide.
- inorganic compounds such as alkali metal
- Sodium ethoxide, potassium ethoxide, potassium tert-butoxide and Dimethoxymagnesium also organic bases, for example tertiary amines such as trimethylamine, triethylamine, tributylamine, di-isopropylethylamine and N-methylpiperidine, pyridine, substituted pyridines such as collidine, lutidine and 4-dimethylaminopyridine and bicyclic amines into consideration.
- Particularly preferred are alkali metal and alkaline earth metal hydroxides, alkali metal and alkaline earth metal carbonates and tertiary amines.
- the bases are generally equimolar, but can also be used in excess or optionally as a solvent.
- the starting materials are generally reacted with one another in equimolar amounts. It may be advantageous for the yield to use III.4 in an excess based on III.3a or 111.3a ".
- Suitable acids for cleaving the protective groups are, for example, inorganic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid, sulfuric acid and perchloric acid, Lewis acids such as boron trifluoride, aluminum trichloride, ferric chloride, tin IV chloride, titanium IV chloride and zinc II chloride, and organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, toluenesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, citric acid and trifluoroacetic acid.
- inorganic acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid, sulfuric acid and perchloric acid
- Lewis acids such as boron trifluoride, aluminum trichloride, ferric chloride, tin IV chloride, titanium IV chloride and zinc II chloride
- organic acids such as formic acid, acetic acid, propionic acid,
- the acids are generally used in catalytic amounts, but they can also be used equimolar, in excess or optionally as a solvent.
- the cyclization to the piperazinedione ring takes place with compounds of the formula III in which R 2 is hydrogen.
- R 2 is hydrogen.
- Compounds of the formula I ' are obtained.
- the introduction of the group R 2 different from hydrogen can in this case take place at the level of formula I.
- Preferred alkylating agents are Dialkyl sulfates, dialkyl carbonates, alkyl chlorides and alkyl bromides, preferably dimethyl sulfate, dimethyl carbonate, methyl chloride and methyl bromide, is usually carried out at temperatures of 0 0 C to 12O 0 C, preferably 2O 0 C to 8O 0 C, in an inert organic solvent in the presence of a base [see. Bioorg. Med. Chem. Lett. 2001, 11 (19), 2647-9].
- Suitable solvents are water, aliphatic hydrocarbons such as pentane, hexane, cyclohexane and petroleum ether, aromatic hydrocarbons such as toluene, o-, m- and p-xylene, ethylbenzene, mesitylene, halogenated hydrocarbons such as methylene chloride, chloroform and chlorobenzene, dichlorobenzene, benzotrifluoride, Ether like
- Suitable bases are generally inorganic compounds such as alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide, alkali metal and alkaline earth metal oxides such as lithium oxide, sodium oxide, calcium oxide and magnesium oxide, alkali metal and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and Calcium hydride, alkali metal amides such as lithium amide, sodium amide and potassium amide, alkali metal and alkaline earth metal carbonates such as lithium carbonate, potassium carbonate and calcium carbonate, and alkali metal hydrogencarbonates such as sodium hydrogencarbonate, organometallic compounds, in particular alkali metal alkyls such as methyllithium, butyl lithium and phenyl lithium, alkylmagnesium halides such as methylmagnesium chloride and alkali metal and alkaline earth metal alkoxides, such as sodium methoxide, sodium ethanolate, potassium ethanol
- alkali metal amides such as lithium amide, sodium amide and potassium amide
- alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide.
- the bases are generally used in catalytic amounts, but they can also be used equimolar, in excess or optionally as solvent.
- Suitable solvents are aliphatic hydrocarbons such as pentane, hexane, cyclohexane and petroleum ether, aromatic hydrocarbons such as toluene, o-, m- and p-xylene, ethylbenzene, mesitylene, halogenated hydrocarbons such as methylene chloride, chloroform and chlorobenzene, dichlorobenzene, benzotrifluoride, ethers such as diethyl ether, Diisopropyl ether, tert-butyl methyl ether, cyclopentyl methyl ether, dioxane, anisole and THF, nitriles such as acetonitrile and propionitrile, ketones such as acetone, methyl ethyl ketone, diethyl ketone and tert-butyl methyl ketone, alcohols such as methanol, ethanol, n-propanol, isoprop
- Suitable bases are generally inorganic compounds such as alkali metal and alkaline earth metal hydroxides such as lithium hydroxide, sodium hydroxide, potassium hydroxide and calcium hydroxide, alkali metal and alkaline earth metal acetates such as lithium acetate, sodium acetate, potassium acetate and calcium acetate, alkali metal and alkaline earth metal oxides such as lithium oxide, sodium oxide, calcium oxide and magnesium oxide, alkali metal and alkaline earth metal hydrides such as lithium hydride, sodium hydride, potassium hydride and calcium hydride, alkali metal amides such as lithium amide, sodium amide and potassium amide, alkali metal and alkaline earth metal carbonates such as lithium carbonate, potassium carbonate and calcium carbonate and alkali metal hydrogen carbonates such as sodium bicarbonate, as well as organic bases, eg tertiary amines such as trimethylamine, triethylamine, tributylamine, diisopropylethylamine and N-
- Acidic catalysts include inorganic acids such as hydrofluoric acid, acetic acid, hydrobromic acid, sulfuric acid and perchloric acid, Lewis acids such as boron trifluoride, aluminum trichloride, ferric chloride, tin IV chloride, titanium IV chloride and zinc II chloride , and organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, toluenesulfonic acid, benzenesulfonic acid, camphorsulfonic acid, citric acid and trifluoroacetic acid use.
- inorganic acids such as hydrofluoric acid, acetic acid, hydrobromic acid, sulfuric acid and perchloric acid
- Lewis acids such as boron trifluoride, aluminum trichloride, ferric chloride, tin IV chloride, titanium IV chloride and zinc II chloride
- organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, toluene
- boron trifluoride ferric chloride, tin IV chloride, titanium (IV) chloride and zinc (II) chloride, toluenesulfonic acid, benzenesulfonic acid, trifluoroacetic acid, in particular boron trifluoride, iron (III) chloride, toluenesulfonic acid, trifluoroacetic acid.
- the acids are generally used in catalytic amounts, but they can also be used equimolar, in excess or optionally as a solvent.
- the starting materials are generally reacted with one another in equimolar amounts. It may be advantageous for the yield to employ R 2 -X in an excess relative to I '.
- X is a nucleophilic cleavable
- alkylating agents are dialkyl sulfates, dialkyl carbonates, alkyl chlorides and alkyl bromides, preferably dimethyl sulfate, dimethyl carbonate, methyl chloride and methyl bromide.
- X is a nucleophilic cleavable
- acylating agents are carboxylic acid anhydrides and carboxylic acid chlorides, preferably acetic anhydride and acetyl chloride.
- R 1 and R 2 preferably denote alkylcarbonyl, such as acetyl, or alkyl, such as methyl, ethyl, allyl, propargyl and
- Methylpropargyl in particular methyl and acetyl.
- the alkylation or acylation of the compounds I is usually carried out under the conditions mentioned above for the analogous reactions of the compounds I '.
- the starting materials are generally reacted with one another in equimolar amounts. It may be advantageous for the yield to use R 1 -X or R 2 -X in an excess based on I ".
- reaction mixtures are worked up in a customary manner, for example by mixing with water, separating the phases and optionally chromatographic purification of the crude products.
- Some of the intermediate and end products are in the form of colorless or pale brownish, viscous oils which are obtained under reduced pressure and moderately elevated temperature of volatile fractions freed or cleaned. If the intermediate and end products are obtained as solids, the purification can also be carried out by recrystallization or trituration.
- the starting materials required for the preparation of the compounds I are z.T. commercially available, known in the literature or can be prepared according to the literature.
- the naturally occurring ⁇ -amino acids or their alkyl esters of the formula III.1 are preferably used in the process according to the invention.
- the following amino acids are suitable as compounds of the formula III.1:
- Preferred compounds of the formula III.1 are the alkyl esters, in particular the methyl or ethyl esters of the abovementioned amino acids.
- Halogen fluorine, chlorine, bromine and iodine
- Alkyl saturated, straight-chain or branched hydrocarbon radicals having 1 to 4, 6, 8 or 10 carbon atoms, for example C 1 -C 6 -alkyl, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methyl-propyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1, 1-dimethylpropyl, 1, 2-dimethylpropyl, 1 Methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3- Dimethylbutyl, 1-ethylbutyl, 2-e
- Haloalkyl straight-chain or branched alkyl groups having 1 to 2, 4 or 6 carbon atoms (as mentioned above), in which groups the hydrogen atoms may be partially or completely replaced by halogen atoms as mentioned above: in particular C 1 -C 2 -haloalkyl, such as chloromethyl, bromomethyl, Dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoro ethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2- Trichloroe
- Alkenyl unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 4, 6, 8 or 10 carbon atoms and one or two double bonds in any position, e.g. C2-C6 alkenyl such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1 - Methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3 Methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl 3-Butenyl, 1, 1-dimethyl
- Haloalkenyl unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 10 carbon atoms and one or two double bonds in any position (as mentioned above), wherein in these groups, the hydrogen atoms partially or completely replaced by halogen atoms as mentioned above, in particular fluorine, chlorine and bromine could be;
- Alkynyl straight-chain or branched hydrocarbon groups having 2 to 4, 6, 8 or 10 carbon atoms and one or two triple bonds in any position, for example C 2 -C 6 alkynyl, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2 Butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl 3-butynyl, 3-methyl-1-butynyl, 1, 1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl , 1-methyl-2-pentynyl
- 5- or 6-membered heterocyclyl containing one to three nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms e.g. 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-isothiazolidinyl, 5- isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 2-imidazolidinyl, 4-imidazolid
- 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom 5-membered heteroaryl groups, which besides carbon atoms can contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members.
- 6-membered heteroaryl containing one to three or one to four nitrogen atoms 6-membered ring heteroaryl groups, which in addition to carbon atoms may contain one to three or one to four nitrogen atoms as ring members, e.g. 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl;
- R 1 is hydrogen or methyl or ethyl, in particular methyl.
- R 2 is C 1 -C 4 -alkyl, in particular methyl.
- R 3 is C 1 -C 4 -alkyl, in particular methyl.
- R 4 is phenyl-C 1 -C 4 -alkyl, in particular benzyl, where the ring is substituted by one to five, especially one to three groups R a and
- R a is halogen, CN, NO 2, C -C alkyl 4 -alkyl, C 2 -C 4 alkenyl, C 2 -C kinyl 4 -alkyl, Ci-C 4 alkoxy,
- phenoxy and benzyloxy which cyclic groups by groups such as halogen, CN, NO2, Ci-C 8 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 - Al kynyl, C 3 -C 8 - cycloalkyl, Ci-C 8 -haloalkyl, Ci-C 8 alkoxy, Ci-C 8 haloalkoxy may be substituted;
- R 11 is C 1 -C 6 -alkyl, C 3 -C 8 -alkenyl, C 3 -C 8 -alkynyl. In another embodiment, R 4 is unsubstituted benzyl.
- R 1 , R 2 , R 3 , R 4 , R 5 independently of one another are hydrogen and C 1 -C 4 -alkyl
- R 41 , R 42 are hydrogen, C 1 -C 8 -alkyl and C 1 -C 8 -alkoxy, where the groups gene by halo-, OH, CN, Ci-C 8 alkyl-Al, C 8 haloalkyl, C 3 -C 8 cycloalkyl, Ci-C 8 alkoxy,
- R a is halogen, CN, NO2, Ci-C alkyl 4 -alkyl, C 2 -C 4 alkenyl, C 2 -C kinyl 4 -alkyl, Ci-C 4 alkoxy,
- 0-C (O) R 11 phenoxy and benzyloxy, which contain cyclic groups by groups such as halogen, CN, NO 2 , C 1 -C 4 -alkyl, C 2 -C 8 -alkynyl, C 2 -C 8 - Al kynyl, C 3 -C 8 - cycloalkyl, Ci-C 8 -haloalkyl, Ci-C 8 alkoxy, Ci-C 8 haloalkoxy may be substituted;
- R 11 is C 1 -C 6 -alkyl, C 3 -C 8 -alkenyl, C 3 -C 8 -alkynyl, n is O, 1, 2, 3, 4 or 5.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011522466A JP2011530559A (ja) | 2008-08-13 | 2009-07-30 | ピペラジンジオン誘導体を調製する方法 |
CN2009801306685A CN102119153A (zh) | 2008-08-13 | 2009-07-30 | 制备哌嗪二酮衍生物的方法 |
US13/058,677 US20110144336A1 (en) | 2008-08-13 | 2009-07-30 | Method for Preparation of Piperazindione Derivatives |
EP09781280A EP2318379A1 (de) | 2008-08-13 | 2009-07-30 | Verfahren zur herstellung von piperazindion-derivaten |
BRPI0916949-0A BRPI0916949A2 (pt) | 2008-08-13 | 2009-07-30 | Processo para a preparação de derivados de piperazinadiona, e, uso dos compostos. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08162326.6 | 2008-08-13 | ||
EP08162326 | 2008-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010018067A1 true WO2010018067A1 (de) | 2010-02-18 |
Family
ID=41211739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/059859 WO2010018067A1 (de) | 2008-08-13 | 2009-07-30 | Verfahren zur herstellung von piperazindion-derivaten |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110144336A1 (de) |
EP (1) | EP2318379A1 (de) |
JP (1) | JP2011530559A (de) |
CN (1) | CN102119153A (de) |
AR (1) | AR073036A1 (de) |
BR (1) | BRPI0916949A2 (de) |
WO (1) | WO2010018067A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10123803B2 (en) | 2007-10-17 | 2018-11-13 | Covidien Lp | Methods of managing neurovascular obstructions |
EP2315760B1 (de) * | 2008-07-29 | 2013-03-06 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
KR20110063849A (ko) * | 2008-10-02 | 2011-06-14 | 바스프 에스이 | 제초 효과를 갖는 피페라진 화합물 |
US11084794B2 (en) * | 2018-10-30 | 2021-08-10 | Triad National Security, Llc | Controlled cyclization of peptoids to form chiral diketopiperazines |
WO2024075813A1 (ja) * | 2022-10-07 | 2024-04-11 | 学校法人中部大学 | ジケトピペラジン化合物を用いるポリペプチド合成 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0493813A1 (de) * | 1990-12-27 | 1992-07-08 | Ajinomoto Co., Inc. | 2,5-Dioxopiperazinverbindung und Verfahren zu ihrer Herstellung |
WO1995021832A1 (en) * | 1994-02-14 | 1995-08-17 | Xenova Limited | Pharmaceutical piperazine compounds |
WO1998005292A2 (en) * | 1996-08-08 | 1998-02-12 | Schering Corporation | Piperidine and piperazine derivatives and their use as muscarinic antagonists |
WO1999048889A1 (en) | 1998-03-25 | 1999-09-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
WO2001053290A1 (fr) | 2000-01-18 | 2001-07-26 | Nippon Steel Corporation | Inhibiteurs de la division cellulaire et procede de production de ces inhibiteurs |
WO2005011699A1 (en) | 2003-08-01 | 2005-02-10 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
WO2006111583A1 (de) | 2005-04-22 | 2006-10-26 | Basf Aktiengesellschaft | Verfahren zur herstellung von 1,3,5-trifluor-2,4,6-trichlorbenzol aus fluorbenzolderivaten |
WO2007077201A1 (de) | 2006-01-02 | 2007-07-12 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
WO2007077247A1 (de) | 2006-01-05 | 2007-07-12 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171379A1 (en) * | 2001-12-28 | 2003-09-11 | Jacobs Robert S. | Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds |
SI2054394T1 (sl) * | 2007-06-12 | 2010-02-26 | Basf Se | Spojine piperazinov s herbicidno aktivnostjo |
US20100190794A1 (en) * | 2007-06-12 | 2010-07-29 | Basf Se | Herbicidally Active Composition |
EP2315760B1 (de) * | 2008-07-29 | 2013-03-06 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
-
2009
- 2009-07-30 CN CN2009801306685A patent/CN102119153A/zh active Pending
- 2009-07-30 US US13/058,677 patent/US20110144336A1/en not_active Abandoned
- 2009-07-30 WO PCT/EP2009/059859 patent/WO2010018067A1/de active Application Filing
- 2009-07-30 BR BRPI0916949-0A patent/BRPI0916949A2/pt not_active IP Right Cessation
- 2009-07-30 JP JP2011522466A patent/JP2011530559A/ja not_active Withdrawn
- 2009-07-30 EP EP09781280A patent/EP2318379A1/de not_active Withdrawn
- 2009-08-12 AR ARP090103121A patent/AR073036A1/es unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0493813A1 (de) * | 1990-12-27 | 1992-07-08 | Ajinomoto Co., Inc. | 2,5-Dioxopiperazinverbindung und Verfahren zu ihrer Herstellung |
WO1995021832A1 (en) * | 1994-02-14 | 1995-08-17 | Xenova Limited | Pharmaceutical piperazine compounds |
WO1998005292A2 (en) * | 1996-08-08 | 1998-02-12 | Schering Corporation | Piperidine and piperazine derivatives and their use as muscarinic antagonists |
WO1999048889A1 (en) | 1998-03-25 | 1999-09-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
WO2001053290A1 (fr) | 2000-01-18 | 2001-07-26 | Nippon Steel Corporation | Inhibiteurs de la division cellulaire et procede de production de ces inhibiteurs |
WO2005011699A1 (en) | 2003-08-01 | 2005-02-10 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
WO2006111583A1 (de) | 2005-04-22 | 2006-10-26 | Basf Aktiengesellschaft | Verfahren zur herstellung von 1,3,5-trifluor-2,4,6-trichlorbenzol aus fluorbenzolderivaten |
WO2007077201A1 (de) | 2006-01-02 | 2007-07-12 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
WO2007077247A1 (de) | 2006-01-05 | 2007-07-12 | Basf Se | Piperazinverbindungen mit herbizider wirkung |
WO2008079945A2 (en) * | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
Non-Patent Citations (17)
Title |
---|
AKABORI ET AL, NIPPON KAGAKU ZASSHI - JOURNAL OF THE CHEMICAL SOCIETY OF JAPAN,PURE CHEMISTRY SECTION, NIPPON KAGAKUKAI, TOKYO, JP, vol. 73, 1 January 1952 (1952-01-01), pages 112 - 115, XP009124797, ISSN: 0369-5387 * |
ARCH. PHARM., vol. 338, no. 5, 2005, pages 281 - 90 |
BIOORG. MED CHEM. LETT., vol. 11, no. 19, 2001, pages 2647 - 9 |
BO LIU ET AL: "A Novel and Facile Method to Synthesize (R)- and (S)-2-methylpiperazine", SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS GROUP, PHILADELPHIA, PA, vol. 34, no. 22, 1 January 2004 (2004-01-01), pages 4111 - 4118, XP009124819, ISSN: 0039-7911 * |
CHUNG-GI SHIN ET AL: "alpha,Beta-Unsaturated Carboxylic Acid Derivatives. 20. N-Methylation of alpha-Dehydroamino Acid Ester and Its Cyclic Dipeptide from Various Routes", HETEROCYCLES, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 16, no. 9, 1 September 1981 (1981-09-01), pages 1573 - 1578, XP009124782, ISSN: 0385-5414 * |
GREEN; WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE |
HETEROCYCLES, vol. 52, no. 3, 2000, pages 1231 - 1239 |
INT. J. PREPT. PROT. RES., vol. 28, no. 6, 1986, pages 579 - 585 |
J. AGRIC. FOOD CHEM., vol. 49, 2001, pages 2298 - 2301 |
J. BULL. CHEM. SOC. JPN., vol. 48, 1975, pages 2584 |
J. ORG. CHEM., vol. 69, no. 5, 2004, pages 1542 - 47 |
JOURNAL OF ANTIBIOTICS, vol. 49, no. 10, 1996, pages 1014 - 1021 |
SYNTH. COMMUN., vol. 34, no. 22, 2004, pages 4111 - 18 |
SYNTH. COMMUN., vol. 35, no. 8, 2005, pages 1129 - 34 |
TETRAHEDRON LETT., 1971, pages 2499 |
TETRAHEDRON, vol. 58, no. 6, 2002, pages 1173 - 1183 |
THL, vol. 36, no. 24, 1995, pages 4295 - 8 |
Also Published As
Publication number | Publication date |
---|---|
JP2011530559A (ja) | 2011-12-22 |
AR073036A1 (es) | 2010-10-06 |
EP2318379A1 (de) | 2011-05-11 |
CN102119153A (zh) | 2011-07-06 |
BRPI0916949A2 (pt) | 2015-08-18 |
US20110144336A1 (en) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2164831B1 (de) | Verfahren zur herstellung n-substituierter (3-dihalomethyl-1-methyl-pyrazol-4-yl)carboxamide | |
EP2086944B1 (de) | Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten | |
ZA200608382B (en) | 5,6-dialkyl-7-amino-traizolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds | |
WO2002006286A2 (en) | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
HU218488B (hu) | Új eljárás imidazo-piridin-származékok előállítására | |
EP2885281B1 (de) | Carbamat-benzoxazinones zur herstellung von triazin-benzoxazinone | |
JP4080743B2 (ja) | 除草剤誘導体の製法 | |
WO2010018067A1 (de) | Verfahren zur herstellung von piperazindion-derivaten | |
JP4114948B2 (ja) | α−メトキシイミノカルボン酸メチルアミドの製造方法およびその中間生成物 | |
NO156048B (no) | Analogifremgangsmaate for fremstilling av farmasoeytisk aktive imidazopyridinerivater | |
JP7044766B2 (ja) | 3-フルオロアルキル-5-ピラゾールカルボキシレート類及び3-フルオロアルキル-5-ピラゾールカルボン酸類を調製する方法 | |
CA1092133A (en) | Cyanoacetic acid anilide derivatives, process for their manufacture and compositions containing them | |
US8357803B2 (en) | Process for the preparation of 2,3,4,9-tetrahydro-1H-β-carbolin-3-carboxylic acid esters | |
WO2010069819A1 (de) | Verfahren zur herstellung von piperazindion-derivaten | |
JP4672148B2 (ja) | 1−置換−5−ヒドロキシピラゾールの製造方法 | |
KR101616434B1 (ko) | 7,8-디메톡시-1,3-디하이드로-2h-3-벤즈아제핀-2-온 화합물의 합성 방법 및 이바브라딘 합성에서의 적용 | |
JP2002535311A (ja) | マロノニトリル及びアセトンからの3‐アミノ−2−クロロ−4‐メチルピリジンの合成 | |
JP3449714B2 (ja) | 2−アミノ−桂皮酸エステル | |
Fujisaki et al. | Preparation and chemical properties of 5-dialkylaminomethylhydantoins and 2-thio-analogues | |
WO2021110859A1 (en) | One step process for the preparation of phenyl ethyl amine derivatives | |
JPH04210984A (ja) | 環生成されたイミノチアゾールの製法及び中間体 | |
JPH08239351A (ja) | 6−ヒドロキシ−3−ピリジンカルボン酸エステルの製造に用いる中間体及びその製造方法 | |
ZA200606942B (en) | 6-(2-chloro-5-halophenyl)-triazolopyrimidine, method for production and use thereof for controlling fungal pests and the agents comprising the same | |
BR112019021122A2 (pt) | Processo para preparar um composto e compostos | |
Cież et al. | Synthesis of novel, chiral, water-soluble isothiazole derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980130668.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09781280 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 286/KOLNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011522466 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13058677 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009781280 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0916949 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110208 |